Sara Nik
Stock Analyst at H.C. Wainwright
(0.27)
# 4,355
Out of 4,581 analysts
45
Total ratings
13.3%
Success rate
-11.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sara Nik
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRIS Curis | Reiterated: Buy | $17 → $43 | $4.83 | +790.27% | 9 | Jul 24, 2026 | |
| TVRD Tvardi Therapeutics | Maintained: Buy | $9 | $2.44 | +268.85% | 2 | Jul 7, 2026 | |
| STO: CANTA Cantargia AB (publ) | Reiterated: Buy | kr 14.00 | kr 1.87 | +649.06% | 9 | Jul 2, 2026 | |
| MBRX Moleculin Biotech | Reiterated: Buy | $22 | $2.19 | +904.57% | 16 | Jul 1, 2026 | |
| KTTA Pasithea Therapeutics | Reiterated: Buy | $3 | $0.45 | +566.67% | 8 | Jul 1, 2026 | |
| KAPA Kairos Pharma | Reiterated: Buy | $12 | $0.308 | +3,796.10% | 1 | Aug 13, 2025 |
Curis
Jul 24, 2026
Reiterated: Buy
Price Target: $17 → $43
Current: $4.83
Upside: +790.27%
Tvardi Therapeutics
Jul 7, 2026
Maintained: Buy
Price Target: $9
Current: $2.44
Upside: +268.85%
Cantargia AB (publ)
Jul 2, 2026
Reiterated: Buy
Price Target: kr 14.00
Current: kr 1.87
Upside: +649.06%
Moleculin Biotech
Jul 1, 2026
Reiterated: Buy
Price Target: $22
Current: $2.19
Upside: +904.57%
Pasithea Therapeutics
Jul 1, 2026
Reiterated: Buy
Price Target: $3
Current: $0.45
Upside: +566.67%
Kairos Pharma
Aug 13, 2025
Reiterated: Buy
Price Target: $12
Current: $0.308
Upside: +3,796.10%